Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKLB4O)

• Drug Name: UTPgammaS Drug Info
• Synonyms: UTP-Gamma-S; CHEMBL220200; UTPgammaS; UTP..gamma..S; AC1NSKQ9; SCHEMBL338166; GTPL1735; BDBM50205417; (dihydroxyphosphinothioyloxy-hydroxyphosphoryl) [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate; dihydroxyphosphinothioyl [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5311494
  TTD Drug ID: DMKLB4O

Molecule-Related Drug Atlas

Drug(s) Targeting P2Y purinoceptor 4 (P2RY4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
INS 316	DMTHMEI	Lung cancer	2C25.0	Discontinued in Phase 3	[4]
PPADS	DMWHN3T	Discovery agent	N.A.	Investigative	[5]
CTP	DM4T62U	Discovery agent	N.A.	Investigative	[4]
ITP	DMVFITX	Discovery agent	N.A.	Investigative	[4]
2-amino-uridine-5'-monophosphate	DMO792L	Discovery agent	N.A.	Investigative	[6]
MRS2927	DMB2A7Q	Discovery agent	N.A.	Investigative	[7]
MRS4062	DMWKXGP	Discovery agent	N.A.	Investigative	[7]
N4-phenylethoxycytidine-5'-triphosphate	DM7KX2V	Discovery agent	N.A.	Investigative	[7]
(N)methanocarba-UTP	DM6SV7I	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting P2Y purinoceptor 2 (P2RY2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Diquafosol	DM64QG9	Dry eye disease	9E1Z	Phase 3	[9]
INS-37217	DMF93RQ	Cystic fibrosis	CA25	Phase 2	[9]
INS 316	DMTHMEI	Lung cancer	2C25.0	Discontinued in Phase 3	[10]
PSB-0963	DMBDVJ1	Discovery agent	N.A.	Investigative	[11]
RB 2	DMCEFUW	Discovery agent	N.A.	Investigative	[12]
Acid blue 25	DMCU6XV	Discovery agent	N.A.	Investigative	[11]
5BrUTP	DMEVRH4	Discovery agent	N.A.	Investigative	[2]
2-thioUTP	DMJZ5V0	Discovery agent	N.A.	Investigative	[13]
SB-416	DMJW72O	Discovery agent	N.A.	Investigative	[12]
MDT-006	DMSF4UI	Constipation	DD91.1	Investigative	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P2Y purinoceptor 2 (P2RY2)	TTOZHQC	P2RY2_HUMAN	Agonist	[2]
P2Y purinoceptor 4 (P2RY4)	TT24DGP	P2RY4_HUMAN	Agonist	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1735).
• [2] Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol. 1995 Sep;116(1):1619-27.
• [3] Enzymatic synthesis of UTP gamma S, a potent hydrolysis resistant agonist of P2U-purinoceptors. Br J Pharmacol. 1996 Jan;117(1):203-9.
• [4] ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor. Mol Pharmacol. 2000 May;57(5):926-31.
• [5] Development of selective agonists and antagonists of P2Y receptors. Purinergic Signal. 2009 Mar;5(1):75-89.
• [6] Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2011 Apr 28;54(8):2878-90.
• [7] Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate delta-ester modifications as selective agonists of the P2Y(4) receptor. J Med Chem. 2011 Jun 23;54(12):4018-33.
• [8] Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. J Med Chem. 2002 Jan 3;45(1):208-18.
• [9] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [10] Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol. 2001 Aug;32(2):122-8.
• [11] Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
• [12] Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 1;18(1):223-7.
• [13] Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2006 Nov 30;49(24):7076-87.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 324).